Advertisement
ABBV vs JNJ
Which Stock Would AI Choose? AbbVie (ABBV) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- Both ABBV and JNJ have posted strong year-to-date gains, yet their recent market momentum is diverging sharply.
- AbbVie's relative performance is being driven by immunology growth and pipeline catalysts, while Johnson & Johnson faces a slowing medical device (MedTech) segment and a large talc litigation charge.
- ABBV trades at a much higher trailing price-to-earnings (P/E) multiple, while JNJ carries a lower valuation and a higher dividend yield.
- Johnson & Johnson's pharmaceutical arm is thriving, but its MedTech business is decelerating and weighing on overall sentiment.
- Investors weighing growth momentum may favor AbbVie, while income-focused investors may find Johnson & Johnson's stability and yield more compelling.
Introduction
AbbVie and Johnson & Johnson are two of the largest names in global healthcare, yet they offer investors very different profiles. This stock comparison examines how their business models, growth drivers, recent market positioning, and risk factors stack up in the current environment. AbbVie is a pure-play biopharmaceutical company built around immunology, oncology, and neuroscience franchises, while Johnson & Johnson is a diversified healthcare conglomerate spanning pharmaceuticals and medical devices. Traders tracking momentum and relative performance, as well as long-term investors evaluating stability and income, may find this side-by-side analysis a useful starting point for understanding how these two bellwethers are performing today.
ABBV Overview and Recent Performance
AbbVie is a research-based biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics. In recent market activity, the stock has traded near the upper end of its 52-week range, reflecting a sustained run supported by its newer immunology drugs, Skyrizi and Rinvoq. Management has reported that erosion from the blockbuster drug Humira, which lost patent exclusivity, has been more than offset by growth from these and other platforms.
Recent weeks have brought a steady flow of clinical and regulatory developments, including two U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designations for the investigational cancer drug telisotuzumab adizutecan (Temab-A) in colorectal and lung cancer. The company also raised its full-year revenue guidance following a strong first quarter, though it modestly trimmed its adjusted earnings outlook to account for the pending Apogee Therapeutics acquisition. Sentiment remains broadly positive, but the stock's elevated trailing P/E multiple and insider selling have prompted some debate about valuation.
JNJ Overview and Recent Performance
Johnson & Johnson operates two principal segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). In recent market activity, the stock pulled back after its latest quarterly report, even though results beat Wall Street expectations and full-year guidance was raised. The decline was driven less by earnings quality than by a sharp slowdown in MedTech growth and a large one-time charge tied to a proposed resolution of ovarian talc litigation.
Within pharmaceuticals, growth has been robust, led by strong sales of Tremfya, Darzalex, Caplyta, and Spravato, which are helping to offset declining revenue from Stelara as it faces biosimilar competition. However, MedTech growth has decelerated across recent quarters, pressured by Middle East disruption, European budget cuts, pricing pressure in China, and softer demand for Abiomed heart pumps. Management has also indicated it is weighing a spinoff of its orthopedics business, a move that could sharpen portfolio focus but adds near-term uncertainty.
Trending AI Robots
For traders who prefer a data-driven, automated approach to navigating comparisons like this one, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing AI Trading Bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and set of securities. Because not every bot suits every market environment, only the most relevant and best-performing bots earn a place in the Trending AI Robots section. This curated selection lets users quickly identify automated strategies aligned with current conditions. Explore the Trending AI Robots page to see which bots are currently leading the market.
Head-to-Head Comparison
The clearest contrast between these two names lies in diversification and growth composition. Johnson & Johnson's broad exposure across pharmaceuticals and medical devices historically provided balance, but that balance is now working against it as MedTech decelerates. AbbVie, by contrast, is more concentrated but is currently benefiting from a focused, high-momentum immunology franchise.
On valuation, the gap is substantial. AbbVie's trailing P/E is elevated relative to its own history, reflecting optimism around its pipeline, while Johnson & Johnson trades at a comparatively lower multiple and offers a higher dividend yield. Growth drivers differ as well: AbbVie leans on Skyrizi, Rinvoq, and a rich late-stage pipeline, whereas Johnson & Johnson is relying on oncology and immunology drugs to offset biosimilar erosion in Stelara. Risk factors also diverge, with AbbVie exposed to pipeline execution and competitive threats, and Johnson & Johnson facing litigation overhangs, MedTech headwinds, and potential restructuring costs. From a market-sentiment standpoint, AbbVie's trend has been steadier, while Johnson & Johnson's pullback has introduced near-term uncertainty.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst flow, and relative positioning, Tickeron's AI would currently lean toward ABBV. The stock's steadier uptrend, supportive immunology momentum, and dense pipeline of upcoming data readouts present a more favorable near-term setup. JNJ, by contrast, is contending with a decelerating device segment, litigation-related charges, and restructuring questions that are likely to keep volatility elevated. That said, the verdict is probabilistic rather than definitive, and Johnson & Johnson's lower valuation, higher dividend, and diversified model may still appeal to investors prioritizing stability over momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and JNJ is a Buy.
ABBV's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ABBV turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 33 of 46 cases over the following month. The odds of a continued upward trend are 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 54 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
Following a +0.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 218 of 359 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 220 of 355 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 17 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 38%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-85.048) is very low in comparison to the industry average of (-2.799). ABBV has a moderately high P/E Ratio (80.689) as compared to the industry average of (21.101). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.041) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
JNJ in downward trend: price dove below 50-day moving average on October 23, 2026
JNJ moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 19 of 32 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 59%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Oscillator exited the oversold zone, 14 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 47%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 39 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 21 of 47 cases over the following month. The odds of a continued upward trend are 45%.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.482) is normal, around the industry mean (-2.799). P/E Ratio (30.219) is within average values for comparable stocks, (21.101). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.041) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
ABBV | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 2 | 4 | |
SMR RATING 1..100 | 1 | 37 | |
PRICE GROWTH RATING 1..100 | 12 | 44 | |
P/E GROWTH RATING 1..100 | 72 | 8 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for JNJ (77). This means that ABBV’s stock grew significantly faster than JNJ’s over the last 12 months.
ABBV's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as JNJ (4). This means that ABBV’s stock grew similarly to JNJ’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for JNJ (37). This means that ABBV’s stock grew somewhat faster than JNJ’s over the last 12 months.
ABBV's Price Growth Rating (12) in the Pharmaceuticals Major industry is in the same range as JNJ (44). This means that ABBV’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's P/E Growth Rating (8) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (72). This means that JNJ’s stock grew somewhat faster than ABBV’s over the last 12 months.
| ABBV | JNJ | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 38% | 3 days ago 47% |
| Stochastic ODDS (%) | 3 days ago 38% | 3 days ago 48% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 46% |
| MACD ODDS (%) | 3 days ago 72% | 3 days ago 45% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 47% |
| TrendMonth ODDS (%) | 3 days ago 64% | 3 days ago 45% |
| Advances ODDS (%) | 3 days ago 61% | 14 days ago 46% |
| Declines ODDS (%) | 25 days ago 46% | 21 days ago 40% |
| BollingerBands ODDS (%) | 3 days ago 40% | 3 days ago 31% |
| Aroon ODDS (%) | 3 days ago 62% | 3 days ago 38% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while JNJ’s FA Score has 2 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- JNJ’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 4 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 4 bearish.
- JNJ’s TA Score: 4 bullish, 6 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +0.08% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +3.23% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.08%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +4.21%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 30, 2026.
JNJ is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.16% | ||
| NVS - ABBV | 50% Loosely correlated | -3.30% | ||
| JNJ - ABBV | 49% Loosely correlated | -1.42% | ||
| AMGN - ABBV | 48% Loosely correlated | -1.79% | ||
| BMY - ABBV | 47% Loosely correlated | -2.41% | ||
| BIIB - ABBV | 41% Loosely correlated | -1.24% | ||
More | ||||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with GSK. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then GSK could also see price increases.